Clinical trial
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute…
NCT00064584 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00064584 |
|---|---|
| Title | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) |
| Official title | Tolerability and PK/PD of Multiple Oral Doses of CT53518 in Patients With Acute Myelogenous Leukemia |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | CT53518 |
| Enrollment | 60 |
| Start date | May 1, 2002 |
| Primary completion | Jan 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Jul 10, 2003 |
| Last update posted | Mar 24, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: